Characteristics and Prognosis of Primary Treatment-naïve Oral Cavity Squamous Cell Carcinoma in Norway, a Descriptive Retrospective Study
Overview
Authors
Affiliations
Objectives: Incidence of oral cavity squamous cell carcinomas is rising worldwide, and population characterization is important to follow for future trends. The aim of this retrospective study was to present a large cohort of primary oral cavity squamous cell carcinoma from all four health regions of Norway, with descriptive clinicopathological characteristics and five-year survival outcomes.
Materials And Methods: Patients diagnosed with primary treatment-naïve oral cavity squamous cell carcinomas at all four university hospitals in Norway between 2005-2009 were retrospectively included in this study. Clinicopathological data from the electronic health records were compared to survival data.
Results: A total of 535 patients with primary treatment-naïve oral cavity squamous cell carcinomas were identified. The median survival follow-up time was 48 months (range 0-125 months) after treatment. The median five-year overall survival was found to be 47%. Median five-year disease-specific survival was 52%, ranging from 80% for stage I to 33% for stage IV patients. For patients given treatment with curative intent, the overall survival was found to be 56% and disease-specific survival 62%. Median age at diagnosis was 67 years (range 24-101 years), 64 years for men and 72 years for women. The male: female ratio was 1.2. No gender difference was found in neither tumor status (p = 0.180) nor node status (p = 0.266), but both factors influenced significantly on survival (p<0.001 for both).
Conclusions: We present a large cohort of primary treatment-naïve oral cavity squamous cell carcinomas in Norway. Five-year disease-specific survival was 52%, and patients eligible for curative treatment had a five-year disease-specific survival up to 62%.
Abu Taha S, Hejleh T, Wahbeh L, Alzibdeh A, Berawi M, Qambar M Front Oncol. 2024; 14:1443367.
PMID: 39464708 PMC: 11502470. DOI: 10.3389/fonc.2024.1443367.
Sellaeg K, Schwienbacher R, Kranz M, Aamodt A, Wirsing A, Berge G Front Oncol. 2024; 14:1343839.
PMID: 38812785 PMC: 11133644. DOI: 10.3389/fonc.2024.1343839.
Tumor Microenvironment and Immune Response in Lip Cancer.
Gkegka A, Koukourakis M, Lambropoulou M, Giatromanolaki A Cancers (Basel). 2023; 15(5).
PMID: 36900270 PMC: 10001350. DOI: 10.3390/cancers15051478.
Soland T, Solhaug M, Bjerkli I, Schreurs O, Sapkota D Eur J Oral Sci. 2022; 130(3):e12866.
PMID: 35363406 PMC: 9321830. DOI: 10.1111/eos.12866.
Shabbir A, Waheed H, Ahmed S, Shaikh S, Farooqui W BMC Oral Health. 2022; 22(1):63.
PMID: 35260133 PMC: 8905853. DOI: 10.1186/s12903-022-02052-1.